---
title: "Psilocybin (COMP360) in Treatment-resistant depression: Place in treatment, anticipated use, and care setting"
description: "Formulary evidence on Psilocybin (COMP360) in Treatment-resistant depression: Place in treatment, anticipated use, and care setting. Topics: VA/DoD guideline: recommendation against psilocybin outside a research setting, CANMAT 2023 update: psilocybin-assisted psychotherapy considered investigational, CANMAT task force: psilocybin an experimental treatment for use within clinical trials, EMA depression guideline: psychedelic development in treatment-resistant depression and a controlled environment, and 6 further topics. 11 evidence topics quoted from 13 sources."
canonical: "https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/product-information-and-disease-description/place-in-treatment-anticipated-use-and-care-setting"
published: "2026-11-18T10:42:20-05:00"
modified: "2026-11-18T10:42:20-05:00"
---

# Psilocybin (COMP360) in Treatment-resistant depression: Place in treatment, anticipated use, and care setting

<a id="heading-2.2.2.2"></a>

## 2.2.2.2 Place in Treatment, Anticipated Use, and Care Setting

<a id="topic-2.2.2.2-1"></a>

### Summary

COMPASS has submitted a New Drug Application for COMP360 for TRD, which its press release defines as an inadequate response to two or more courses of antidepressants of adequate dose and duration. Guidelines that address psilocybin restrict it to research: the VA/DoD guideline recommends against psilocybin for MDD “outside of a research setting”, with very low confidence in the evidence; the CANMAT guideline update considers psilocybin-assisted psychotherapies “investigational treatments”; and a CANMAT task force recommends use primarily within clinical trials. The EMA guideline recommends starting psychedelic development in TRD and states that psychedelics need administration “in a controlled environment”. ICER's draft scope assesses psilocybin 25 mg in adults with MDD without psychotic features after two or more failed adequate antidepressant trials in the current episode, with esketamine, intravenous ketamine, and rTMS as comparators focusing on US outpatient settings. The company's November 2026 investor presentation states that dosing and monitoring will take place at a certified treatment center, and its quarterly release cites more than 8,500 treatment centers. The company described one or two initial administrations followed by episodic dosing per physician decision. Payer panel participants named head-to-head trials against esketamine or other active comparators as the most important evidence for coverage.

Source: [COMPASS Pathways NDA submission release (2026)](https://ir.compasspathways.com/News--Events-/news/news-details/2026/Compass-Pathways-Completes-COMP360-Psilocybin-New-Drug-Application-to-U-S--FDA-for-Treatment-Resistant-Depression/default.aspx); [VA/DoD (2022)](https://www.healthquality.va.gov/guidelines/MH/mdd/VADoDMDDCPGFinal508.pdf); [Lam et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11351064/); [Rosenblat et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9720483/); [EMA (2025)](https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-medicinal-products-treatment-depression-revision-3_en.pdf); [ICER draft scope (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_TRD_Draft-Scope_For-Publication_102126-1.pdf); [COMPASS Pathways November investor presentation (2026)](https://s204.q4cdn.com/927483861/files/content_files/DRAFT_CMPS-investor-presentation_NOV026-1.pdf); [COMPASS Pathways third quarter 2026 results (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000078/q32026pressrelease.htm); [COMPASS Pathways third quarter earnings call transcript (2026)](https://www.fool.com/earnings/call-transcripts/2026/11/03/compass-pathways-cmps-q3-2026-earnings-call-transcript/); [Flavin et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13520776/)

<a id="topic-2.2.2.2-2"></a>

### VA/DoD guideline: recommendation against psilocybin outside a research setting

> “Given the limited information on the safety and efficacy of psilocybin, MDMA, cannabis, and other unapproved pharmacologic treatments, we recommend against using these agents for MDD outside of a research setting.”
> “The Work Group’s confidence in the quality of the evidence was very low.”
> “Further, there are significant resource use and feasibility challenges to implementing psilocybin and MDMA treatments since dosing protocols to date have included prolonged therapeutic interventions and monitoring (between eight to 12 hours) following administration.”
> “There are also substantial pharmacy storage and dispensing implications, with both psilocybin and MDMA currently being classified as U.S. Drug Enforcement Agency (DEA) Schedule 1 compounds.”

Source: [VA/DoD (2022)](https://www.healthquality.va.gov/guidelines/MH/mdd/VADoDMDDCPGFinal508.pdf)

<a id="topic-2.2.2.2-3"></a>

### CANMAT 2023 update: psilocybin-assisted psychotherapy considered investigational

> “Psychedelic-assisted psychotherapy was recently reviewed in a CANMAT Task Force Report.”
> “Although these results are promising, they are limited by ongoing methodological issues (e.g., lack of blinding, inadequate assessment of expectancy bias, heterogeneity of psychological support, and lack of long-term safety data).”
> “Hence, psilocybin- and other psychedelic-assisted psychotherapies are considered investigational treatments”

Source: [Lam et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11351064/)

<a id="topic-2.2.2.2-4"></a>

### CANMAT task force: psilocybin an experimental treatment for use within clinical trials

> “There is currently only low-level evidence to support the efficacy and safety of psychedelics for major depressive disorder.”
> “As such, Canadian Network for Mood and Anxiety Treatments considers psilocybin an experimental treatment and recommends its use primarily within clinical trials, or, less commonly, through the special access program in rare, special circumstances.”

Source: [Rosenblat et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9720483/)

<a id="topic-2.2.2.2-5"></a>

### EMA depression guideline: psychedelic development in treatment-resistant depression and a controlled environment

> “Psychedelics are currently being recognised in psychiatry as potential treatment options to treat various medical conditions including MDD.”
> “Due to potential significant alterations of perception and behaviour, it is recommended to start development in a more severely affected population, such as patients with treatment resistant depression (section 4.4.1.).”
> “Therefore, psychedelics need to be administered in a controlled environment.”
> “The monotherapy setting with psychedelics alone may not be applicable or feasible.”

Source: [EMA (2025)](https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-medicinal-products-treatment-depression-revision-3_en.pdf)

<a id="topic-2.2.2.2-6"></a>

### NICE guideline recommendations for treatment-resistant depression

> “See the NICE interventional procedures guidance on implanted vagus nerve stimulation for treatment-resistant depression.”
> “Esketamine nasal spray is not recommended in NICE technology appraisal guidance for treating treatment-resistant depression.”

Source: [NICE (2022)](https://www.nice.org.uk/guidance/ng222/chapter/Recommendations)

<a id="topic-2.2.2.2-7"></a>

### ICER assessment scope: population, intervention, comparators, and setting

> “The population of focus for the review is adults ages 18 years and older with major depressive disorder, without psychotic features, and for whom two or more prior antidepressants prescribed at adequate dose and duration, during the current episode, have not resulted in adequate therapeutic benefit.”
> “Psilocybin (25 mg)”
> “Esketamine (SPRAVATO®, Janssen) / Intravenous (IV) ketamine, an anesthetic agent used off-label for TRD”
> “Repetitive Transcranial Magnetic Stimulation (rTMS)”
> “All relevant settings will be considered, with a focus on outpatient settings in the United States.”
> “Appropriate interventions in TRD include augmentation of medication therapy with an antipsychotic medication.”

Source: [ICER draft scope (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_TRD_Draft-Scope_For-Publication_102126-1.pdf)

<a id="topic-2.2.2.2-8"></a>

### Company statements on intended position in treatment-resistant depression

> “This 1-year data further supports the belief that, if approved, COMP360 could establish a new standard of care in TRD that can be life-changing for patients”

Source: [COMPASS Pathways COMP005 52-week release (2026)](https://ir.compasspathways.com/News--Events-/news/news-details/2026/Compass-Pathways-New-52-Week-Topline-Open-Label-Data-from-Phase-3-COMP005-Trial-Demonstrates-Additional-Benefit-from-Another-COMP360-Dose-in-Part-C-Extending-Durability-Out-to-1-Year/default.aspx)

> “we are confident that clinicians will adopt COMP360 as the treatment of choice for patients with TRD.”
> “Today, less than 3% of these patients are accessing the only marketed and approved TRD treatment, SPRAVATO, due largely to the burden associated with the required frequency of dosing.”

Source: [COMPASS Pathways third quarter earnings call transcript (2026)](https://www.fool.com/earnings/call-transcripts/2026/11/03/compass-pathways-cmps-q3-2026-earnings-call-transcript/)

<a id="topic-2.2.2.2-9"></a>

### Anticipated dosing pattern: one or two initial administrations, then episodic retreatment

> “what we would envisage and target is after one or two initial administrations, that then there is the provision for episodic dosing per physician decision.”

Source: [COMPASS Pathways third quarter earnings call transcript (2026)](https://www.fool.com/earnings/call-transcripts/2026/11/03/compass-pathways-cmps-q3-2026-earnings-call-transcript/)

> “We believe COMP360 has the potential to transform mental health care by moving beyond daily or frequent administration toward just a few treatments per year”

Source: [COMPASS Pathways November investor presentation (2026)](https://s204.q4cdn.com/927483861/files/content_files/DRAFT_CMPS-investor-presentation_NOV026-1.pdf)

<a id="topic-2.2.2.2-10"></a>

### Anticipated care setting: certified interventional psychiatry treatment centers

> “Patient self-administers oral capsule, monitored by a licensed HCP during session”
> “Dosing and monitoring to take place at a certified treatment center”
> “Well-established Infrastructure of Interventional Psychiatry Treatment Centers in Place and Preparing to Offer COMP360”

Source: [COMPASS Pathways November investor presentation (2026)](https://s204.q4cdn.com/927483861/files/content_files/DRAFT_CMPS-investor-presentation_NOV026-1.pdf)

> “COMP360 expected to fit seamlessly within an established and expanding infrastructure of more than 8,500 treatment centers”

Source: [COMPASS Pathways third quarter 2026 results (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000078/q32026pressrelease.htm)

> “At launch, we will leverage the well-established interventional psychiatry treatment center infrastructure.”
> “These treatment sites are specifically designed to support in-office treatments for products that require multi-hour support and monitoring.”

Source: [COMPASS Pathways third quarter earnings call transcript (2026)](https://www.fool.com/earnings/call-transcripts/2026/11/03/compass-pathways-cmps-q3-2026-earnings-call-transcript/)

> “Our business and commercialization strategy for our investigational COMP360 psilocybin treatment depends on our ability to identify, qualify, prepare and support third-party treatment sites which will administer COMP360 psilocybin treatment.”

Source: [COMPASS Pathways Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000020/cmps-20251231.htm)

<a id="topic-2.2.2.2-11"></a>

### Payer panel perspectives on the place of psilocybin in therapy

> “Perspectives among participants on the current evidence for psilocybin in TRD were mixed, with some indicating it is compelling or promising and their organization would likely cover upon FDA approval and others indicating it is uncertain or insufficient and would likely adopt a wait-and-see approach to coverage.”
> “These participants cited the lack of clinical treatment guidelines, comparative studies, and cost-effectiveness data as particular challenges when trying to determine the place in therapy of a new treatment and make coverage decisions.”
> “Participants indicated that the most important evidence required to support coverage of psilocybin would be head-to-head trials vs esketamine or other active comparators such as SGAs.”

Source: [Flavin et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13520776/)

## Related pages
- [Psilocybin (COMP360): Treatment-resistant depression](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Terms and abbreviations](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/terms-and-abbreviations.md)
- [Psilocybin (COMP360): Treatment-resistant depression](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/executive-summary) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/executive-summary.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Product information and disease description](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/product-information-and-disease-description.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Clinical evidence](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/clinical-evidence.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Economic information and modeling report](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/economics) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/economics.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: References](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/references) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/references.md)
